Medicus Pharma (MDCX)
0.16
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13D Medicus Pharma Ltd. Filed by: Bokhari Raza
September 14, 2026 4:39 PM - SEC Filing
Form 424B3 Medicus Pharma Ltd.
September 14, 2026 9:38 AM - SEC Filing
Form 8-K Medicus Pharma Ltd. For: Sep 11
September 14, 2026 8:06 AM - SEC Filing
Form 8-K Medicus Pharma Ltd. For: Sep 04
September 11, 2026 8:00 AM - SEC Filing
Medicus Pharma publishes Phase 2 SkinJect study report
September 10, 2026 7:30 AM - StreetInsider
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
September 10, 2026 7:30 AM - StreetInsider
Medicus Pharma shifts focus to CD228V oncology program
September 8, 2026 7:30 AM - StreetInsider
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
September 8, 2026 7:30 AM - StreetInsider
Form 424B3 Medicus Pharma Ltd.
August 13, 2026 6:04 AM - SEC Filing
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026 6:01 PM - StreetInsider
Form 10-Q Medicus Pharma Ltd. For: Jun 30
August 12, 2026 5:20 PM - SEC Filing
Medicus Pharma names Dr. Faisal Mehmud CEO of UK unit Antev
August 3, 2026 7:31 AM - StreetInsider
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
August 3, 2026 7:30 AM - StreetInsider
Medicus Pharma gets UAE approval for endometriosis drug study
July 31, 2026 7:30 AM - StreetInsider
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
July 31, 2026 7:30 AM - StreetInsider
Alliance Global Partners Starts Medicus Pharma Ltd. (MDCX) at Buy
July 28, 2026 7:08 AM - StreetInsider
Medicus Pharma gets FDA clearance to start Gorlin Syndrome study
July 27, 2026 8:17 AM - StreetInsider
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
July 27, 2026 8:17 AM - StreetInsider
Medicus Pharma gets FDA feedback and IRB nod for smaller Phase 2 trial
July 16, 2026 7:30 AM - StreetInsider
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
July 16, 2026 7:30 AM - StreetInsider
New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group
July 4, 2026 12:27 PM - StreetInsider
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
June 22, 2026 7:30 AM - StreetInsider
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
June 20, 2026 1:30 PM - StreetInsider
Full Article List
